AXDX Kapitalisasi Akuntansi Accelerate Diagnostics, Inc.

Accelerate Diagnostics (AXDX) production facilities in the United States develop equipment for the rapid detection of bacteria and therapy selection. The business is currently in a phase of active market expansion, offering the Pheno system to save lives in hospitals by 2026. The company's price evolution, where the indicator stands at -0.06, demonstrates resilience to crises and autumn-winter demand for emergency tests.

Accelerate Diagnostics (AXDX) bases its business on the commercialization of high-margin Pheno systems and consumables for rapid sepsis diagnostics. The difference between total assets and liabilities, reflected in the trend of the company's balance sheet capitalization, allows for an assessment of the real value of net assets and the issuer's resilience to market shocks, while excessive growth in this metric may signal a decline in capital efficiency.